Rubius Therapeutics Inc (NASDAQ:RUBY) rose 8.2% during trading on Wednesday . The stock traded as high as $9.08 and last traded at $9.02, approximately 259,578 shares were traded during mid-day trading. A decline of 29% from the average daily volume of 364,968 shares. The stock had previously closed at $8.34.

RUBY has been the topic of several research reports. JPMorgan Chase & Co. cut Rubius Therapeutics from an “overweight” rating to a “neutral” rating and set a $9.00 target price on the stock. in a research note on Friday, January 31st. Zacks Investment Research cut Rubius Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, February 5th. HC Wainwright restated a “buy” rating and issued a $40.00 target price on shares of Rubius Therapeutics in a research note on Friday, November 15th. Finally, BidaskClub upgraded Rubius Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, February 5th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and three have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and an average target price of $17.40.

The stock has a market cap of $687.89 million, a P/E ratio of -4.63 and a beta of 2.31. The company has a 50 day simple moving average of $8.82 and a 200 day simple moving average of $9.65. The company has a current ratio of 9.83, a quick ratio of 9.83 and a debt-to-equity ratio of 0.30.

Rubius Therapeutics (NASDAQ:RUBY) last released its earnings results on Thursday, November 14th. The company reported ($0.59) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.53) by ($0.06). During the same quarter in the previous year, the company posted ($0.42) earnings per share. As a group, sell-side analysts expect that Rubius Therapeutics Inc will post -2.04 earnings per share for the current year.

In other Rubius Therapeutics news, insider Christopher L. Carpenter sold 48,000 shares of the business’s stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $13.48, for a total value of $647,040.00. Following the sale, the insider now owns 82,843 shares in the company, valued at approximately $1,116,723.64. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 58.40% of the company’s stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Bank of Montreal Can increased its position in shares of Rubius Therapeutics by 45.0% during the 4th quarter. Bank of Montreal Can now owns 4,437 shares of the company’s stock worth $42,000 after purchasing an additional 1,377 shares during the last quarter. NEXT Financial Group Inc acquired a new position in shares of Rubius Therapeutics during the 4th quarter worth approximately $60,000. Tower Research Capital LLC TRC increased its position in shares of Rubius Therapeutics by 650.2% during the 4th quarter. Tower Research Capital LLC TRC now owns 6,722 shares of the company’s stock worth $64,000 after purchasing an additional 5,826 shares during the last quarter. Virtu Financial LLC acquired a new position in shares of Rubius Therapeutics during the 4th quarter worth approximately $106,000. Finally, Marshall Wace LLP acquired a new position in shares of Rubius Therapeutics during the 4th quarter worth approximately $111,000.

Rubius Therapeutics Company Profile (NASDAQ:RUBY)

Rubius Therapeutics, Inc focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing various RCTs, such as RTX-134 for treatment of phenylketonuria; RTX-Uricase for treatment of chronic refractory gout; RTX-CBS for treatment of homocystinuria; and RTX-OxOx for the treatment of second-line hyperoxaluria.

Featured Story: Correction

Receive News & Ratings for Rubius Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rubius Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.